AIDS VACCINE TRIALS

'06 YEAR IN REVIEW

IN 2006, 13 NEW PREVENTIVE AIDS VACCINE CLINICAL TRIALS began in 8 countries around the world—highlighted in yellow on the large map. Countries where trials started in 2003-2005 and are still ongoing are outlined in white. The map also shows HIV prevalence ranges for all countries where the latest data is available (2005 UNAIDS estimates). The green map below illustrates the HIV incidence figures for 2006 by region.

40 million
people currently infected with HIV

2006 UNAIDS estimate

ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV IN 2006

Region	
North America	43,000
Caribbean	27,000
Latin America	140,000
Western and Central Europe	22,000
Eastern Europe and Central Asia	270,000
East Asia	100,000
North Africa and Middle East	68,000
South and South-East Asia	860,000
Sub-Saharan Africa	2.8 million
Oceania	7,100
TOTAL	**4.3 million**

Data from 2006 UNAIDS epidemic update.

KEY

TIMELINE

MONTH
Countries (Number of sites)
TRIAL NUMBER - Phase - Number of volunteers
Vaccine
ORGANIZER, MANUFACTURER (see over for definitions)

VACCINE TYPE
DNA — Viral vector — Protein

TRIALS
- Countries where trials began in 2006
- Other countries where trials are ongoing

HIV PREVALENCE
For adults age 15-49

< 0.1%	1.0% – <5.0%
0.1% – < 0.5%	5.0% – < 15.0%
0.5% – < 1.0%	15.0% – 34.0%

2005 prevalence data from UNAIDS, May 2006. Countries in white indicate data unavailable.

SCALE
0 — 2,000 miles
Mollweide Interrupted Projection

THE 2006 TIME LINE

JANUARY
Sweden
HIVIS 02 - Ph I - 38 vol.
MVA-CMDR
KI, SMI, USMHRP

JANUARY
US (3), Peru (2)
HVTN 064 - Ph I - 120 vol.
EP-1043, EP HIV-1090
NIAID, Pharmexa-Epimmune

MARCH
Russian Federation
HVRF-380-131004
Ph I - 15 vol.
VICHREPOL with polyoxi-donium adjuvant
MII, RFMES

MARCH
US (5)
HVTN 065 - Ph I - 122 vol.
Prime: HIVB DNA pGA2/JS7#2
Boost: MVA-HIV 62
NIAID, Geovax

MARCH
US (5)
HVTN 068 - Ph I - 66 vol.
Prime: VRC-HIVDNA-016-00-VP or VRC-ADV-014-00-VP
Boost: VRC-ADV-014-00-VP NIAID

MARCH
US
RV 138 - Ph I - 36 vol.
ALVAC-HIV vCP205
USMHRP

**MAY**
Kenya, Uganda, Tanzania
RV 172 - Ph I/II - 324 vol.
Prime: VRC-HIVDNA-016-00-VP
Boost: VRC-ADV-014-00-VP
USMHRP, NIAID

MAY
US
VRC 011 (06-I-0149) - Ph I - 60 vol.
Prime: VRC-HIVDNA-016-00-VP
Boost: VRC-ADV-014-00-VP
NIAID

SEPTEMBER
UK
C86P1 - Ph I - 30 vol.
Prime: HIV gp140 with LTK63
Boost: HIV gp140 with MF59
SGUL, RPh., NV

OCTOBER
Uganda
HPTN 027 - Ph I - 50 vol.
ALVAC-HIV vCP1521
NIAID, Sanofi

OCTOBER
US
DHO-0586 - Ph I - 8 vol.
ADMVA
ADARC, IAVI

NOVEMBER
US (6)
HVTN 069 - Ph Ib - 90 vol.
Prime: VRC-HIVDNA-009-00-VP
Boost: VRC-ADV-014-00-VP
NIAID

DECEMBER
Tanzania
HIVIS 03 - Ph I/II - 60 vol.
Prime: HIVIS DNA
Boost: MVA-CMDR
MUCHS, KI, SMI, Vecura, USMHRP